UK Markets close in 5 hrs 6 mins

Silence Therapeutics plc (SLNCF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
29.850.00 (0.00%)
At close: 12:05PM EDT

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Aug. 15, 2022.

Sign in to post a message.
  • M
    Monte
    I Emailed Silence Therapeutics about SLN 360.
    I texted Silence Therapeutics about SLN 360.
    I did my best to contact upper management regarding SLN 360.
    The company failed to respond to all my efforts.
    I had to ask myself, could they have not at least responded?
    So now I will make every effort to find out if they can help.
    Below is what I had Emailed and texted to Silence Therapeutics
    management. Why have they not answered my simple questions?

    Dear Sirs,

    In your recent clinical trials for SLN 360 the press release stated the trial was conducted in healthy adults with high Lp(a).
    Can you please clarify and elaborate on the word health adults. Did these people in the trials have a history of genetically
    inherited familial hypercholesterolemia? My fiancé is suffering from a very high familial hypercholesterolemia, very high numbers on her Lp(a), and so we need to know whether
    or not to somehow get in contact with your upcoming clinical trial, if it includes people with familial hypercholesterolemia?
    My fiancé is fifty years old, and so we are very concerned, and it is in a way an emergency that if possible she can be included in your next clinical trial.
    Also her older brother has the same infliction.
    Thank you very much.

    Sincerely
  • S
    StockPickerExtraordinaire
    Shanghai’s Hansoh inks development deal with UK biotech
    For the second time this week, Chinese biotech Hansoh made a deal. This time, the $1 billion+ deal is with the London-based  siRNA firm Silence Therapeutics.

    The two companies announced a collaboration today to develop siRNAs for three undisclosed targets, leveraging Silence’s mRNAi platform. Hansoh will pay Silence $16 million upfront, with a potential $1.3 billion more in additional milestones plus royalties on net product sales.

    Hansoh will have the exclusive option to license rights to the first two targets in China, Hong Kong, Macau and Taiwan following the completion of Phase I studies. Silence will retain exclusive rights for those two targets in all other markets, maintaining responsibility for all activities until Hansoh exercises its option.

    Silence will also retain responsibility for development outside those Asian markets after the Phase I studies are complete.

    Hansoh will also have the exclusive option to license global rights for a third target at the point of IND filing, maintaining responsibility for all development activities after exercising that option.

    “We are excited to partner with Silence, a pioneer in siRNA therapeutic development with decades of scientific and technical experience,” said executive director of Hansoh’s board Eliza Sun in a statement.
  • S
    StockPickerExtraordinaire
    Don't forget that SILENCE is DeListing from the LSE (London) and is Listing soley on the NASDAQ. I think a good idea and with a Billion $ contract with a Chinese Company should rise.
  • A
    Alfonse
    Let's share some thoughts, why the interest in ARWR.
  • Y
    Yahoo Finance Insights
    Silence Therapeutics is down 6.73% to 20.51
  • W
    Will
    Hello Can any old timers if this name advise the how a share of SLN.L converts to a share of SNLCF? Is their a set share ratio and the currency conversion?

    Thank you in advance.
  • Y
    Yahoo Finance Insights
    SLN.L reached a 52 Week low at $54.20
  • Y
    Yahoo Finance Insights
    SLN.L reached a 52 Week low at $47.90
  • Y
    Yahoo Finance Insights
    SLN.L reached a 52 Week low at $46.40
  • Y
    Yahoo Finance Insights
    SLN.L reached a 52 Week low at $48.84
  • Y
    Yahoo Finance Insights
    Silence Therapeutics is up 6.53% to 26.63
  • Y
    Yahoo Finance Insights
    Silence Therapeutics is up 6.98% to 25.14
  • Y
    Yahoo Finance Insights
    SLN.L is down 11.63% to $60.00
  • Y
    Yahoo Finance Insights
    Silence Therapeutics reached a 52 Week low at 14.89
  • Y
    Yahoo Finance Insights
    Silence Therapeutics reached a 52 Week low at 17.20
  • Y
    Yahoo Finance Insights
    Silence Therapeutics reached a 52 Week low at 16.53
  • Y
    Yahoo Finance Insights
    Silence Therapeutics reached a 52 Week low at 14.43
  • Y
    Yahoo Finance Insights
    Silence Therapeutics reached a 52 Week low at 13.60
  • Y
    Yahoo Finance Insights
    Silence Therapeutics reached a 52 Week low at 16.70